Tesamorelin: selected references HeartPep literature library, reviewed 2026-11-16 https://heartpep.com/us/research/library/tesamorelin 1. Makimura H, Feldpausch MN, Rope AM, et al. (2012). Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial Journal of Clinical Endocrinology & Metabolism. DOI: https://doi.org/10.1210/jc.2012-2794 PMID: 23015655 Source: https://pubmed.ncbi.nlm.nih.gov/23015655/ Verification: Abstract / bibliographic record. 2. Falutz J, Potvin D, Mamputu JC, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes. DOI: https://doi.org/10.1097/QAI.0b013e3181cbdaff PMID: 20101189 Source: https://pubmed.ncbi.nlm.nih.gov/20101189/ Verification: Abstract / bibliographic record. 3. Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial The Lancet HIV. DOI: https://doi.org/10.1016/S2352-3018(19)30338-8 PMID: 31611038 Source: https://pubmed.ncbi.nlm.nih.gov/31611038/ Verification: Full text. 4. Colpaert T, Miller G, Goodrum J, et al. (2026). Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS Drug Testing and Analysis. DOI: https://doi.org/10.1002/dta.70189 PMID: 43013893 Source: https://pubmed.ncbi.nlm.nih.gov/43013893/ Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.